Adverse event exchange program for devices needs fixing
This article was originally published in Clinica
A program that regulators around the world can use to exchange confidential information on serious adverse events (SAEs) for medical devices is in need of significant improvements, a survey of users of the scheme has revealed.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
A number of new products have been submitted for review at the European Medicines Agency. While marketing authorization applications from ViiV Healthcare and BioMarin Pharmaceutical are being fast-tracked, a submission from Incyte is not.